Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Juzentaihoto with intravesical BCG in non-muscle invasive bladder cancer
jRCT1061260022Not yet recruiting
- Start
- May 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of juzentaihoto in non-muscle-invasive bladder cancer (NMIBC) (2 arms). Primary endpoints: Rate of achievement of adequate BCG therapy, BCG continuation rate and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
juzentaihoto
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT1061260022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061260022.